methyl angolensate: from the stem bark of Entandrophragma angolense; inhibits gastric acid secretion; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Entandrophragma | genus | [no description available] | Meliaceae | The mahogany plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 419676 |
| MeSH ID | M0244744 |
| Synonym |
|---|
| nsc-117177 |
| methyl angolensate |
| nsc117177 |
| 2629-14-3 |
| angolensic acid methyl ester |
| methyl (1alpha,5beta,13alpha,14beta,17aalpha)-1,14:21,23-diepoxy-4,4-dimethyl-3,16-dioxo-d-homo-24-nor-17-oxa-6,7-secachola-7,20,22-triene-6-carboxylate |
| d-homo-24-nor-17-oxa-6,7-secachola-7,20,22-triene-6-carboxylic acid, 1,14:21,23-diepoxy-4,4-dimethyl-3,16-dioxo-, methyl ester, (1alpha,5beta,13alpha,14beta,17aalpha)- |
| nsc 117177 |
| angolensic acid, methyl ester |
| DTXSID90949151 |
| methyl [4-(furan-3-yl)-4a,7a,9,9-tetramethyl-13-methylidene-2,10-dioxododecahydro-4h-7,12a-methanopyrano[4,3-b][1]benzoxocin-8-yl]acetate |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||